Abstract
Clinical research leverages cancer patient care outcomes. We analyzed the direct impact of clinical trials (CTs) in terms of clinical outcomes and costs related expenses in patients with metastatic renal cell carcinoma (mRCC) and G1-G2 neuroendocrine tumors (mNETs) in the real-life setting.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have